BioCentury
ARTICLE | Company News

FDA approves Kyowa's Poteligeo for CTCL

August 8, 2018 6:31 PM UTC

FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms of cutaneous T cell lymphoma.

The agency approved Poteligeo to treat adults with relapsed or refractory mycosis fungoides or Sézary syndrome who have already received one prior systemic therapy...

BCIQ Company Profiles

Kyowa Kirin Co. Ltd.